| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H18F3N3O6 |
| Molecular Weight | 441.3579 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(OC[C@](C)(O)C(=O)NC2=CC=C(C(=C2)C(F)(F)F)[N+]([O-])=O)C=C1
InChI
InChIKey=YVXVTLGIDOACBJ-SFHVURJKSA-N
InChI=1S/C19H18F3N3O6/c1-11(26)23-12-3-6-14(7-4-12)31-10-18(2,28)17(27)24-13-5-8-16(25(29)30)15(9-13)19(20,21)22/h3-9,28H,10H2,1-2H3,(H,23,26)(H,24,27)/t18-/m0/s1
| Molecular Formula | C19H18F3N3O6 |
| Molecular Weight | 441.3579 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Andarine is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy. Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, tissue-selective for anabolic organs. Andarine had been in phase I clinical trials by GTx for the treatment of cancer-related cachexia and osteoporosis. However, this research has been discontinued.
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Dogs: An intravenous (i.v.) bolus dose of 10 or 3 mg/kg, an oral(p.o.) solution dose of 10 mg/kg, or an oral capsule dose of 10 mg/kgadministered in a packed gelatin capsule
Route of Administration:
Other
